Relating To The Medical Use Of Cannabis.
HB1390 would substantially expand Hawaii’s medical cannabis framework by creating a new licensed “medical cannabis cultivation site collective” system under the Department of Health. The bill sets up a licensing process, annual fees, canopy limits, packaging and labeling rules, testing and recordkeeping requirements, transport documentation, and protections for licensees and their officers, directors, and employees. It also authorizes collectives to cultivate, process, manufacture, and directly sell usable cannabis to qualifying patients and qualifying out-of-state patients within specified quantity limits.
The measure also revises the state’s existing medical cannabis laws in chapter 329. It broadens the list of authorized patient activities, including cultivation, possession of paraphernalia, sharing limited amounts without remuneration, use of cannabis in any form, and participation in testing and manufacturing activities. It changes definitions for qualifying patients, primary caregivers, written certifications, and debilitating medical conditions; allows multiple caregivers for minors in some cases; and removes the prior registration requirement for qualifying out-of-state patients. The bill further updates dispensary rules, tax treatment, data collection, the medical cannabis special fund, and housing-related nondiscrimination protections for patients and cultivation licensees.
HB1390 would amend multiple chapters of the Hawaii Revised Statutes, including chapters 329, 329D, 237, 201, 321, 421J, 514B, and 521, while adding a new chapter for cultivation site collectives. It would shift the Department of Health into a broader regulatory role over medical cannabis cultivation collectives, create a new fee-funded subaccount, exempt most collective cannabis sales from general excise tax except retail consumer sales, and require ongoing reporting of cannabis program data. The bill would also expand legal protections for patients, caregivers, and cultivation licensees, while preserving limits on possession, transport, and law enforcement access.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, amendments, or formal support/opposition in the available context. Based on the bill text and the report description, the measure appears generally pro-expansion of medical cannabis access and industry structure, with an emphasis on patient access, caregiver flexibility, and regulatory clarity. The overall tone of the proposal is permissive toward medical use while retaining licensing, security, and public-safety controls.
The most likely points of contention are the scope of expansion and the regulatory tradeoffs. The bill would allow a new cultivation collective model, permit direct sales by collectives, expand patient cultivation and transport rights, and remove out-of-state patient registration requirements, which could raise concerns about oversight, diversion, and market impacts. At the same time, it imposes canopy limits, testing, packaging, and recordkeeping rules, so supporters may view it as a controlled expansion rather than deregulation. Potentially sensitive issues also include the higher patient possession limits, the ability to manufacture cannabis products, the reduced role of registration for visitors, and the housing/employment nondiscrimination provisions for patients and cultivation licensees.